Northwestern Mutual Wealth Management
FDMT icon

Northwestern Mutual Wealth Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,094
Closed -$10.2K – 4216
2026
Q1 		$10.2K Buy
+1,094
New +$9.52K ﹤0.01% 3059
2025
Q2 		– Sell
-1
Closed -$3 – 3772
2025
Q1 		$3 Hold
1
– – ﹤0.01% 3636
2024
Q4 		$6 Sell
1
-66
-99% -$518 ﹤0.01% 3562
2024
Q3 		$724 Buy
67
+66
+6,600% +$1.09K ﹤0.01% 3293
2024
Q2 		$21 Hold
1
– – ﹤0.01% 3448
2024
Q1 		$32 Buy
+1
New +$26 ﹤0.01% 3490

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Northwestern Mutual Wealth Management's FDMT Position: Q2 2026 in Review

Northwestern Mutual Wealth Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 1,094 shares — an estimated $10.2K sold.

Northwestern Mutual Wealth Management first reported a position in FDMT in Q1 2024 and held it in 6 quarters. The position peaked at $10.2K in Q1 2026. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Northwestern Mutual Wealth Management reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 1,094 4D Molecular Therapeutics shares in Q2 2026, an estimated $10.2K.
  • Northwestern Mutual Wealth Management first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 6 quarters.
  • Northwestern Mutual Wealth Management's 4D Molecular Therapeutics position peaked at $10.2K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.